UPDATED 09/24/2010. Market withdrawal of all lots of product until root cause of previously reported thromboembolic events can be determined and corrected.
Octagam (Immune Globulin Intravenous (human)) 5% Liquid Preparation: Market Withdrawal - Risk of Thromboembolic Events
August 25th, 2010 · No Comments
Tags: FDA · FDA Alerts
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.